PF-219,061

PF-219,061
Systematic (IUPAC) name
(R)-3-(4-propylmorpholin-2-yl)phenol
Clinical data
Routes of
administration		 Nasal
Identifiers
CAS Number 710654-74-3 YesY
PubChem CID 9794475
ChemSpider 7970242
Chemical data
Formula C13H19NO2
Molar mass 221.295 g/mol
  (verify)

PF-219,061 is a drug developed by Pfizer which acts as a potent and highly selective agonist for the dopamine D3 receptor.[1][2] It is under development as a potential medication for the treatment of female sexual dysfunction.[3][4]

See also

References

  1. ↑ Blagg J, Allerton CM, Batchelor DV, Baxter AD, Burring DJ, Carr CL, Cook AS, Nichols CL, Phipps J, Sanderson VG, Verrier H, Wong S. Design and synthesis of a functionally selective D3 agonist and its in vivo delivery via the intranasal route. Bioorganic and Medicinal Chemistry Letters. 2007 Dec 15;17(24):6691-6. doi:10.1016/j.bmcl.2007.10.059 PMID 17976986
  2. ↑ Brioni JD, Moreland RB. Dopamine D4 receptors and the regulation of penile erection. Drug Discovery Today: Therapeutic Strategies. 2006;3(4):599-604. doi:10.1016/j.ddstr.2006.10.006
  3. ↑ Van Der Graaf et al. SELECTIVE DOPAMINE D3 RECEPTOR AGONISTS FOR THE TREATMENT OF SEXUAL DYSFUNCTION. WIPO Patent WO/2003/051370, granted to Pfizer.
  4. ↑ Attkins NJ, Heatherington AC, Phipps J, Verrier H, Huyghe I. Predictability of intranasal pharmacokinetics in man using pre-clinical pharmacokinetic data with a dopamine 3 receptor agonist, PF-219061. Xenobiotica. 2009 Jul;39(7):523-33. PMID 19480558


This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.